Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

genzyme europe b.v., netherlands - alglucosidase alfa - powder for concentrate for solution for infusion - 5 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

genzyme europe b.v., netherlands - alglucosidase alfa - powder for concentrate for solution for infusion - 5 mg/ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - imiglucerase - powder for solution for infusion - 400unit

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - mesna - solution for infusion or injection - mesna 100 mg/ml - all other therapeutic products

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - mesna - solution for infusion or injection - mesna 100 mg/ml - all other therapeutic products

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - alglucosidase alfa 52.5mg;  ;  ;   - powder for infusion concentrate - 50 mg/10ml - active: alglucosidase alfa 52.5mg       excipient: dibasic sodium phosphate heptahydrate mannitol monobasic sodium phosphate monohydrate nitrogen polysorbate 80 - myozyme is indicated for the long - term treatment of patients with a confirmed diagnosis of pompe disease (acid alfa - glucosidase deficiency).

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: sanofi-aventis philippines, inc.; distributor: sanofi-aventis philippines, inc. - alglucosidase alfa - powder for concentrate for solutions for infusion (iv) - 50 mg

Canada - English - Health Canada

sanofi genzyme, a division of sanofi-aventis canada inc - alglucosidase alfa - powder for solution - 50mg - alglucosidase alfa 50mg - enzymes

European Union - English - EMA (European Medicines Agency)

sanofi b.v. - alglucosidase alfa - glycogen storage disease type ii - other alimentary tract and metabolism products, - myozyme is indicated for long-term enzyme-replacement therapy (ert) in patients with a confirmed diagnosis of pompe disease (acid-α-glucosidase deficiency).in patients with late-onset pompe disease the evidence of efficacy is limited.

Malta - English - Medicines Authority

laboratoire aguettant 1 rue alexander fleming, 69007 lyon, france - norepinephrine - concentrate for solution for infusion - norepinephrine 2 mg/ml - cardiac therapy